02179 瑞科生物－Ｂ
按盤價 
7.550 0.000 (0.000%) 盈利能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 資產回報率 (%) | -25.444% | -34.180% | -44.336% | -24.349% | -32.416% |
| 股東資金回報率 (%) | -41.851% | -43.338% | -197.906% | N/A | 43.271% |
| 資本運用回報率 (%) | -32.833% | -36.489% | -36.943% | -18.130% | -33.828% |
邊際利潤分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 毛利率 (%) | N/A | N/A | N/A | N/A | N/A |
| 未計利息、稅項、折舊及攤銷前利潤率 (%) | N/A | N/A | N/A | N/A | N/A |
| 稅前邊際利潤率 (%) | N/A | N/A | N/A | N/A | N/A |
| 純利率 (%) | N/A | N/A | N/A | N/A | N/A |
變現能力分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 流動比率 (X) | 2.542 X | 4.316 X | 9.294 X | 12.341 X | 17.454 X |
| 速動比率 (X) | 2.331 X | 4.145 X | 9.125 X | 12.206 X | 17.041 X |
財務槓桿分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 總負債 / 總資產比率 (%) | 51.015% | 28.426% | 12.814% | 196.349% | 174.915% |
| 總債項 / 總資產比率 (%) | 29.767% | 12.237% | 3.997% | 2.495% | 1.296% |
| 淨債項 / 總資產比率 (%) | -8.425% | -45.139% | -57.619% | -31.489% | -12.123% |
| 總債項 / 股東資金比率 (%) | 60.740% | 17.007% | 4.585% | N/A | N/A |
| 長期債項 / 股東資金比率 (%) | 55.044% | 15.697% | 4.115% | N/A | N/A |
| 淨債項 / 股東資金比率 (%) | -17.191% | -62.732% | -66.088% | N/A | N/A |
| 淨現金 / (債項) ($) | 1.84億 | 10.43億 | 11.06億 | 3.30億 | 5.17千萬 |
| 每股淨現金 / (債項) ($) | 0.381 | 2.159 | -- | -- | -- |
| 總債項 / 資本運用比率 (%) | 37.358% | 14.270% | 4.310% | 2.640% | 1.353% |
| 利息盈利率 (X) | N/A | N/A | N/A | N/A | N/A |
營運效率分析
| 2023/12 | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| 存貨周轉率日數 (日) | -- | -- | -- | -- | -- |
| 應收貿易帳周轉率日數 (日) | N/A | N/A | N/A | N/A | N/A |
| 應付貿易帳周轉率日數 (日) | N/A | N/A | N/A | N/A | N/A |
| 備註： | 即時報價更新時間為14/08/2024 17:59 |
| 港股即時基本市場行情由香港交易所提供; 香港交易所指定免費發放即時基本市場行情的網站 | |
| 股東應佔溢利/(虧損) () | RMB -571,957,000 |
| 增長率 | -20.859% |
| 每股盈利/(虧損) | RMB -1.190 |
| 每股帳面資產淨值 (¥) | RMB 2.218 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
